SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
Not yet recruiting · NCT03217617 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Primary Immunodeficiency Diseases, X-Linked Combined Immunodeficiency Diseases, X-linked disease, hereditary disease, immune system disorder, inborn error of immunity, severe combined immunodeficiency | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT03217617 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhen Geno-Immune Medical Institute | 43 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Shenzhen | China | 39 |